Abstract
Perioperative haemorrhage is still the major complication of transurethral resection of the prostate (TURP) for benign enlargement of the prostate. Photoselective vaporisation of the prostate (PVP) with the potassium–titanyl–phosphate (KTP) laser has been shown to achieve instant tissue ablation with excellent haemostatic properties. Our aim was to determine the tissue removal capacity, coagulation and haemostatic property of the novel 1,470 nm diode laser, ex vivo and in vivo. We evaluated two prototype diode laser systems at 1,470 nm in an ex vivo, isolated, blood-perfused, porcine kidney model (n = 5; 10 W–50 W) and in an in vivo investigation of beagle prostate (n = 4; 100 W) to assess vaporisation capacities and coagulation properties at different generator settings. The diode laser evaluation was compared with an 80 W KTP laser in the porcine model. After the laser treatment we performed a histological examination to compare the depth of coagulation and vaporisation. The diode laser system (50 W) showed significantly lower (P < 0.0001) capacities for tissue removal than the 80 W KTP laser (0.96 mm ± 0.17 mm and 5.93 mm ± 0.25 mm, respectively, P < 0.0001), while coagulation zones were significantly (P < 0.001) larger in diode laser-treated kidneys (3,39 mm ± 0.93 mm and 1.27 mm ± 0.13 mm, respectively). In vivo, the diode laser displayed rapid ablation of prostatic tissue with no intraoperative haemorrhage. Histological examination revealed coagulation zones of 2.30 mm (±0.26) at 100 W in the diode laser-treated prostates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J (1992) Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 69:603–608
Malek RS, Barrett DM, Kuntzman RS (1998) High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology 51:254–256 doi:10.1016/S0090-4295(97)00613-4
Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA et al (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172:1404–1408 doi:10.1097/01.ju.0000139541.68542.f6
Seitz M, Sroka R, Gratzke C, Schlenker B, Steinbrecher V, Khoder W et al (2007) The diode laser: a novel side-firing approach for laser vaporisation of the human prostate—immediate efficacy and 1-year follow-up. Eur Urol 52:1717–1722 doi:10.1016/j.eururo.2007.06.028
Kohrmann KU, Back W, Bensemann J, Florian J, Weber A, Kahmann F et al (1994) The isolated perfused kidney of the pig: new model to evaluate shock wave-induced lesions. J Endourol 8:105–110
Michel MS, Kohrmann KU, Weber A, Krautschick AW, Alken P (1996) Rotoresect: new technique for resection of the prostate: experimental phase. J Endourol 10:473–478
Reich O, Bachmann A, Schneede P, Zaak D, Sulser T, Hofstetter A (2004) Experimental comparison of high power (80 W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol 171:2502–2504 doi:10.1097/01.ju.0000128803.04158.76
Reich O, Corvin S, Oberneder R, Sroka R, Muschter R, Hofstetter A (2002) In vitro comparison of transurethral vaporization of the prostate (TUVP), resection of the prostate (TURP), and vaporization-resection of the prostate (TUVRP). Urol Res 30:15–20 doi:10.1007/s00240-001-0231-4
Seitz M, Ackermann A, Gratzke C, Schlenker B, Ruszat R, Bachmann A et al (2007) Diode laser: ex vivo studies on vaporization and coagulation characteristics (in German). Urologe A 46:1242–1247 doi:10.1007/s00120-007-1490-7
Doerr W (1950) Use of triphenyltetrazolium chloride as a reduction indicator in histology and histophysiology. Frankf Z Pathol 61:557–573
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547–554 doi:10.1016/j.eururo.2004.07.016
Kaplan SA (2004) AUA Guidelines and their impact on the management of BPH: an update. Rev Urol 6 [Suppl 9]:S46–S52
Reich O, Seitz M, Gratzke C, Schlenker B, Bachmann A, Stief C (2006) Benign prostatic syndrome (BPS). Ablative treatments (in German). Urologe A 45:769–780; quiz 781–762 doi:10.1007/s00120-006-1039-1
Gilling PJ, Fraundorfer MR (1998) Holmium laser prostatectomy: a technique in evolution. Curr Opin Urol 8:11–15 doi:10.1097/00042307-199801000-00003
Kuntzman RS, Malek RS, Barrett DM (1998) High-power potassium titanyl phosphate laser vaporization prostatectomy. Mayo Clin Proc 73:798–801
Cooper TE, Trezek GJ (1972) A probe technique for determining the thermal conductivity of tissue. J Heat Transfer 94:133–140
Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS et al (2007) 980-nm Diode laser: a novel laser technology for vaporization of the prostate. Eur Urol 52:1723–1728 doi:10.1016/j.eururo.2007.06.029
Seitz M, Reich O, Gratzke C, Schlenker B, Karl A, Bader M, Khoder W, Fischer F, Stief C, Sroka R (2008) High-power diode laser at 980 nm for the treatment of benign prostatic hyperplasia: ex vivo investigations on porcine kidneys and human cadaver prostates. Lasers Med Sci: doi:10.1007/s10103-008-0543-5
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seitz, M., Ruszat, R., Bayer, T. et al. Ex vivo and in vivo investigations of the novel 1,470 nm diode laser for potential treatment of benign prostatic enlargement. Lasers Med Sci 24, 419–424 (2009). https://doi.org/10.1007/s10103-008-0591-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-008-0591-x